BioSpace News Archive

Collaboration combines Clario’s eCOA innovations with Cogstate’s expertise in neuroscience research to yield highest quality endpoints.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, presented data demonstrating that the clinical stage selective IRAK4 degrader KT-474 degrades IRAK4 and inhibits cytokine production in different immune and skin cell types at the Society of Investigative Dermatology (SID) Annual Meeting 2022.

BiomX Inc. announced the publication of a scientific paper titled “Exodus: Sequencing-based Pipeline for Quantification of Pooled Variants” in the journal, Bioinformatics.

On June 2 and 3, 2022, the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center will host its sixth international symposium on complex arrhythmias, EPLive 2022.

Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal.

Ei.Ventures Inc. (“Ei”) today announced an update on the previously announced merger with Mycotopia (OTC: TPIA).

Growth in the Virology Specimen Collection Market is mainly driven by the rising prevalence of viral diseases, the increasing prevalence of human papillomavirus (HPV) and cervical cancer.

T-cell immunoreceptor with Ig and ITM domain (TIGIT) is novel immunological checkpoint which is being studied as potential immunotherapeutic target.

Biomea Fusion, Inc. announced that Biomea will attend the H.C. Wainwright Global Investment Conference virtually and will participate in 1x1 meetings held by the conference organizers.

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg.